Adherium (ASK:ADR) touted data from an independent study of its Smartinhaler respiratory disease management tool in children with poorly controlled asthma. The STAAR study was conducted at Sheffield Children’s Hospital in the UK and the results were published this month in Thorax.
The New Zealand-based company found that in children with poorly controlled asthma, introducing its digital adherence monitoring system correlated with a significant reduction in hospital admissions over a 12 month period.
Get the full story at our sister site, Drug Delivery Business News
The post Adherium touts Smartinhaler asthma study appeared first on MassDevice.
from MassDevice http://ift.tt/2f4mUC4
Cap comentari:
Publica un comentari a l'entrada